Nov 12, 2021 7:00am EST Translational Data at SITC 2021 from Adaptimmune’s Phase 1 SURPASS Trial Indicate Adding AKTi to Manufacturing May Contribute to Sustained Antitumor Activity of Next-gen SPEAR T-cells
Nov 11, 2021 9:00am EST Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
Oct 21, 2021 8:00am EDT Adaptimmune to Report Q3 2021 Financial Results and Business Update on Thursday, November 4, 2021
Sep 13, 2021 7:00am EDT Adaptimmune Announces Clinical Responses across Five Solid Tumor Indications with an Overall Response Rate of 36% and Promising Early Durability from its Next-Generation SURPASS Trial
Sep 07, 2021 7:00am EDT Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
Sep 05, 2021 6:15am EDT Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit
Jul 28, 2021 8:11am EDT Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
